Legal & General Group
RARX

Legal & General Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Legal & General Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,823
Closed -$1.05M – 3565
2020
Q1 		$1.05M Buy
21,823
+11,153
+105% +$519K ﹤0.01% 1838
2019
Q4 		$500K Buy
10,670
+4,223
+66% +$187K ﹤0.01% 2218
2019
Q3 		$152K Buy
6,447
+569
+10% +$16.9K ﹤0.01% 2414
2019
Q2 		$177K Buy
5,878
+2,153
+58% +$49.3K ﹤0.01% 2378
2019
Q1 		$84K Buy
3,725
+662
+22% +$14.2K ﹤0.01% 2545
2018
Q4 		$56K Buy
3,063
+1,121
+58% +$17.6K ﹤0.01% 2655
2018
Q3 		$35K Hold
1,942
– – ﹤0.01% 2960
2018
Q2 		$19K Sell
1,942
-1,015
-34% -$7.01K ﹤0.01% 3206
2018
Q1 		$16K Sell
2,957
-301
-9% -$2.15K ﹤0.01% 3153
2017
Q4 		$28K Hold
3,258
– – ﹤0.01% 3089
2017
Q3 		$48K Hold
3,258
– – ﹤0.01% 2923
2017
Q2 		$63K Buy
3,258
+2,013
+162% +$45.4K ﹤0.01% 2837
2017
Q1 		$27K Hold
1,245
– – ﹤0.01% 3009
2016
Q4 		$19K Buy
+1,245
New +$16.9K ﹤0.01% 3127

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Legal & General Group's RARX Position: Q2 2020 in Review

Legal & General Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 21,823 shares — an estimated $1.05M sold.

Legal & General Group first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $1.05M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Legal & General Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Legal & General Group sold 21,823 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.05M.
  • Legal & General Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • Legal & General Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.05M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.